Abstract Purpose: The Na+/I− symporter (NIS) is a key plasma membrane protein that
mediates active iodide (I−) transport in the thyroid, lactating breast, and other tissues …

Objective To investigate the molecular mechanisms underlying the influence of alteration of
iodine trapping on the prognosis of metastatic papillary thyroid carcinomas, focusing on the …

Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have
historically been limited. Recent progress in understanding the pathogenesis of the various …

Context: Radioiodine ablation is commonly used to treat thyroid cancer, but a major
challenge is often the loss of radioiodine avidity of the cancer caused by aberrant silencing …

Radioiodide is an effective therapy for thyroid cancer. This treatment modality exploits the
thyroid-specific expression of the sodium iodide symporter (NIS) gene, which allows rapid …

Context Children present a higher susceptibility to developing thyroid cancer after
radioiodine exposure and also a higher frequency of functional metastases than adults …

Background: Six to 20% of thyroid cancer (TC) patients develop distant metastases, and one-
third become radioiodine refractory (RAIR). Available targeted therapies increase …

Abstract 131I radiation therapy of differentiated thyroid cancer may be compromised by
thyroid stunning (ie, a paradoxical inhibition of radioiodine uptake caused by radiation from …

Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for
thyroid cancer has significantly improved the understanding of the molecular pathogenesis …

Opinion Statement Radioiodine refractory differentiated thyroid cancer (RAI-R DTC) is a
challenging malignancy with limited prognosis and treatment options. Recently, clinical trials …